Clinical study on camrelizumab combined with XELOX regimen in treatment of advanced colon cancer
Objective To explore the clinical efficacy of camrelizumab combined with XELOX regimen in treatment of advanced colon cancer.Methods Patients(94 cases)with advanced colon cancer in People's Hospital of Jingshan from January 2021 to January 2023 were randomly divided into control(47 cases)and treatment(47 cases)group.Patients in the control group were administered with XELOX regimen,Oxaliplatin for injection was given intravenously on 1 d,130 mg/m2;Capecitabine Tablets were taken orally after breakfast and dinner on 1—14 d,1 000 mg/m2,twice daily.Patients in the treatment group were iv administered with Camrelizumab for injection on the basis of the control group,200 mg/time,once every 3 weeks.Patients in two groups were treated for 6 weeks.After treatment,the clinical evaluations were evaluated,the levels of serum CCSA-2,CEA,CA19-9,VEGF-A and VEGFR2,and the QLQ-C30 scores in two groups before and after treatment were compared.Results After treatment,the disease control rate of the treatment group was 80.85%,which was significantly higher than that of the control group(61.70%,P<0.05).After treatment,the serum levels of CCSA-2,CEA,CA19-9,VEGF-An and VEGFR2 in two groups were significantly lower than those before treatment(P<0.05),and the decrease in the treatment group was more significant than that in the control group(P<0.05).After treatment,QLQ-C30 scores in two groups were significantly higher than those before treatment(P<0.05),and the level in the treatment group was significantly higher than that in the control group(P<0.05).Conclusion Camrelizumab combined with XELOX regimen can effectively improve the serum levels of abnormal tumor markers and vascular growth factors such as VEGF-An and VEGFR2 in patients with advanced colon cancer,and improve the quality of life.
Camrelizumab for injectionOxaliplatin for injectionCapecitabine TabletsXELOX schemecolon cancerCEACA19-9VEGF-A
NETL
NSTL
万方数据
